Stela S. Asadurova

Hebron University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Cecilia Carpio

Universitat Autònoma de Barcelona

Santiago Aguadé-Bruix

Universitat Autònoma de Barcelona

Ana Zabalza

Vall d'Hebron Institut de Recerca

Anderson Cardozo Saavedra

Atlanta VA Medical Center

Fabiana María Velázquez

M. Simó

Hebron University

Rubén Vellviure Meiro

Andreu Vilaseca

Vall d'Hebron Institut de Recerca

Gloria Iacoboni

Vall d'Hebron Hospital Universitari

Albert Roque Pérez

Cooperative Institutions

Vall d'Hebron Hospital Universitari

Universitat Autònoma de Barcelona

Vall d'Hebron Institut de Recerca

Hebron University

Universitat de Barcelona

Vall d'Hebron Institute of Oncology

Centre d'Esclerosi Múltiple de Catalunya

Centro de Investigación Biomédica en Red

Centro de Investigación en Red en Enfermedades Cardiovasculares

Bellvitge University Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

P12.20.B [18F]FDG PET/CT BRAIN SCAN IN THE EVALUATION OF NEUROTOXICITY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH CAR-T

Neuro-Oncology (2024)

Stela S. Asadurova Carles Lorenzo‐Bosquet M. Simó Helena Ariño Andreu Vilaseca

Abstract BACKGROUND Neurotoxicity is one of the serious and life-threatening complications of CAR-T treatment in patients with diffuse large B-cell lymphoma. Our objective is to identify the findings in brain PET/CT, their evolution over time, and their clinical correlation. We also aim to compare the sensitivity of PET/CT with magnetic resonance imaging (MRI). MATERIAL AND METHODS This prospective study includes 33 patients with diffuse large B-cell lymphoma treated with CAR-T therapy. Whole-body and brain [18F]FDG PET/CT scans were performed pre-treatment and 30 days post-therapy. In cases of suspected immune effector cell-associated neurotoxicity syndrome (ICANS), urgent structural imaging (CT or MRI) and [18F]FDG PET/CT brain scans were conducted, among other tests. RESULTS The mean age was 62±12 years, with a male-to-female ratio of 19:14. 70% of patients (23/33) developed grade 1, 2, or 3 cytokine release syndrome (CRS). 27% (9/33), all with prior CRS, showed symptoms of ICANS (3/9 G1, 3/9 G2 and 3/9 G3 ICANS). The most common symptoms were tremor, disorientation, and bradypsychia, starting on average on the 7th day post-infusion (range 1 to 10). Urgent [18F]FDG PET/CT brain scans were performed on 7 of the 9 ICANS patients, showing diffuse cortical hypometabolism compatible with encephalopathy in 5 (5/7) and no significant findings in 2/7. At the 30-day post-treatment evaluation, complete normalization was observed in 2/5 patients, improvement with persistent mild global cortical hypometabolism in 2/5, and one patient (1/5) died before the 30 days (with G3 ICANS and severe cortical and subcortical hypometabolism on PET imaging). Urgent brain MRI was performed on the 7 patients with ICANS and urgent [18F]FDG PET brain scans, and it was normal in 5/7 and pathological in 2/7 (both with grade 3 ICANS). CONCLUSION [18F]FDG PET/CT brain scan is useful for the diagnosis and follow-up of patients with CAR-T related neurotoxicity (ICANS) and shows greater sensitivity than MRI. Future studies should determine the relationship between acute phase PET findings and long-term prognosis.

Neurotoxicity

10.1093/neuonc/noae144.233

Cite

Citations (0)

CO133 - GATED-SPECT DE PERFUSIÓN MIOCÁRDICA EN UNA GAMMACÁMARA CZT CARDIODEDICADA

Revista Española de Medicina Nuclear e Imagen Molecular (2023)

Anderson Cardozo Saavedra Fabiana María Velázquez Stela S. Asadurova Rubén Vellviure Meiro Emilio Mariscal Labrador

Gated SPECT

10.1016/s2253-654x(23)00398-0

Cite

Citations (0)